enzymes

  1. P

    Report on Global Markets for Enzymes in Industrial Applications - Focus on North America

    Description Bharat Book introduces a report " Enzymes in Industrial Applications - Focus on North America " This study also discusses the strength and weaknesses of each type/ technology in light of new technologies. qwertyuiopasdfghjklzxcvbnmqwer tyuiopasdfghjklzxcvbnmqwertyuio...
  2. P

    Report on Global Markets for Enzymes in Industrial Applications - Focus on Europe

    Description Bharat Book introduces a report " Enzymes in Industrial Applications - Focus on Europe " This study also discusses the strength and weaknesses of each type/ technology in light of new technologies. qwertyuiopasdfghjklzxcvbnmqwer tyuiopasdfghjklzxcvbnmqwertyuio...
  3. P

    Report on Global Markets for Enzymes in Industrial Applications - Focus on Emerging Markets

    Description Bharat Book introduces a report " Enzymes in Industrial Applications - Focus on Emerging Markets " This study also discusses the strength and weaknesses of each type/ technology in light of new technologies. qwertyuiopasdfghjklzxcvbnmqwer tyuiopasdfghjklzxcvbnmqwertyuio...
  4. P

    Report on Global Markets for Enzymes in Industrial Applications - Focus on Asia

    Description Bharat Book introduces a report " Enzymes in Industrial Applications - Focus on Asia " This study also discusses the strength and weaknesses of each type/ technology in light of new technologies. qwertyuiopasdfghjklzxcvbnmqwer tyuiopasdfghjklzxcvbnmqwertyuio...
  5. P

    Report on Global Markets for Enzymes in Industrial Applications

    Description Bharat Book introduces a report " Global Markets for Enzymes in Industrial Applications " The improvisation of the market, the setbacks and the needs of the market are discussed in this report. qwertyuiopasdfghjklzxcvbnmqwer tyuiopasdfghjklzxcvbnmqwertyuio...
  6. A

    Biocon to sell enzymes biz for $115 mn

    BANGALORE: Biotech major Biocon is selling its enzymes business to Denmark-based Novozymes for $115 million. The transaction, subject to shareholder and regulatory approvals, is expected to be completed by the end of the third quarter of 2007. The move will enable Biocon to focus on its core...
Back
Top